Aim Peptides as ligands have shown the active targeting properties to the receptors like integrins, a family of receptors over-expressed in cancers. The present study was to develop and characterize two peptides modif...Aim Peptides as ligands have shown the active targeting properties to the receptors like integrins, a family of receptors over-expressed in cancers. The present study was to develop and characterize two peptides modified drug-containing liposomes. Methods Argine-glycine-aspartic acid （RGD） tripeptide and glycine-argine-glycine-aspartic acid-serine （GRGDS） pentapeptide were used for modifications on the doxorubicin-loaded sterically stabilized liposomes （SSL-doxorubicin） for the liposome preparation, RGD-SSL-doxorubicin and GRGDS-SSL-doxorubicin, respectively. Characterizations were performed by measurements of the encapsulation efficiency, particle size and zeta potential, release rates in a simulated in vivo environment, and cytotoxicity to ovarian cancer cells. Cell uptake was investigated by flow cytometry and confocal microscopy methods. Results All encapsulation efficiencies of the liposomes were above 95%, and the modifications using RGD or GRGDS did not affect the final encapsulation efficiency. Average particle sizes of the liposomes Were in the range between 105.7 ± 3.5 nm and 130.5 ± 3.0 nm, and zeta potential values were between -3.3 ± 0.3 and -6.1 ± 0.3 mV. Approximately 2/5 of doxorubicin was released from liposomes before 12 h in the simulated in vivo environment containing fetal bovine serum. Inhibitory rates to cancer cells of the modified liposomes were slightly lower as compared to free doxorubicin. Similar phenomena were observed in the uptake measured by flow cytometry and confocal assay. After uptake applying various formulations on the cancer cells, doxorubicin was mainly distributed in the nuclei of SKOV-3 cells. Conclusion Two new doxorubicin-contained liposomes were successfully prepared and modified with argine-glycine-aspartic acid （RGD） tripeptide and glycine-argine-glycine- aspartic acid-serine （GRGDS） pentapeptide. In vitro characterization indicated that modifications did not alter significantly the properties of the sterically stabilized liposomes.展开更多
Oleanolic acid-loaded solid lipid nanoparticles（OA-SLNs）were prepared by using an improved emulsion-solvent evaporation method.The size,zeta potential,encapsulation efficiency,and loading efficiency of OA-SLNs were...Oleanolic acid-loaded solid lipid nanoparticles（OA-SLNs）were prepared by using an improved emulsion-solvent evaporation method.The size,zeta potential,encapsulation efficiency,and loading efficiency of OA-SLNs were（104.5±11.7）nm, （-25.5±1.8）mV,（94.2±3.9）%,and（4.71±0.15）%,respectively.The morphology was illustrated by TEM as sphere stuffed particles.The XRD and DSC spectra confirmed that the OA molecules were dispersed uniformly into SLN matrixes.The results of in vitro release test suggested that OA was released slowly at a rate of 4.88%per hour from SLN preparation,which was consistent with the Zero-order Released Model.In addition,OA-SLNs were stable in artificial gastric juice and artificial intestinal juice.Together,our results provided new data for the potential application of OA-SLNs in oral administration.展开更多
基金National Natural Science Foundation of China(Grant No. 30572261)the 985 Projects (Phase II) of theState Key Laboratory of Natural and Biomimetic Drugs(Peking University, China).
文摘Aim Peptides as ligands have shown the active targeting properties to the receptors like integrins, a family of receptors over-expressed in cancers. The present study was to develop and characterize two peptides modified drug-containing liposomes. Methods Argine-glycine-aspartic acid （RGD） tripeptide and glycine-argine-glycine-aspartic acid-serine （GRGDS） pentapeptide were used for modifications on the doxorubicin-loaded sterically stabilized liposomes （SSL-doxorubicin） for the liposome preparation, RGD-SSL-doxorubicin and GRGDS-SSL-doxorubicin, respectively. Characterizations were performed by measurements of the encapsulation efficiency, particle size and zeta potential, release rates in a simulated in vivo environment, and cytotoxicity to ovarian cancer cells. Cell uptake was investigated by flow cytometry and confocal microscopy methods. Results All encapsulation efficiencies of the liposomes were above 95%, and the modifications using RGD or GRGDS did not affect the final encapsulation efficiency. Average particle sizes of the liposomes Were in the range between 105.7 ± 3.5 nm and 130.5 ± 3.0 nm, and zeta potential values were between -3.3 ± 0.3 and -6.1 ± 0.3 mV. Approximately 2/5 of doxorubicin was released from liposomes before 12 h in the simulated in vivo environment containing fetal bovine serum. Inhibitory rates to cancer cells of the modified liposomes were slightly lower as compared to free doxorubicin. Similar phenomena were observed in the uptake measured by flow cytometry and confocal assay. After uptake applying various formulations on the cancer cells, doxorubicin was mainly distributed in the nuclei of SKOV-3 cells. Conclusion Two new doxorubicin-contained liposomes were successfully prepared and modified with argine-glycine-aspartic acid （RGD） tripeptide and glycine-argine-glycine- aspartic acid-serine （GRGDS） pentapeptide. In vitro characterization indicated that modifications did not alter significantly the properties of the sterically stabilized liposomes.
基金National Basic Research Program of China(973 Program Grant No.2009CB930300)National Integrity Innovational Technology Platform of New Drug and Research and Development (Grant No.2009ZX09310-001).
文摘Oleanolic acid-loaded solid lipid nanoparticles（OA-SLNs）were prepared by using an improved emulsion-solvent evaporation method.The size,zeta potential,encapsulation efficiency,and loading efficiency of OA-SLNs were（104.5±11.7）nm, （-25.5±1.8）mV,（94.2±3.9）%,and（4.71±0.15）%,respectively.The morphology was illustrated by TEM as sphere stuffed particles.The XRD and DSC spectra confirmed that the OA molecules were dispersed uniformly into SLN matrixes.The results of in vitro release test suggested that OA was released slowly at a rate of 4.88%per hour from SLN preparation,which was consistent with the Zero-order Released Model.In addition,OA-SLNs were stable in artificial gastric juice and artificial intestinal juice.Together,our results provided new data for the potential application of OA-SLNs in oral administration.
